Navigation Links
FDA Approves Abbott's XIENCE(TM) V Drug Eluting Stent
Date:7/2/2008

XIENCE V, Only Drug Eluting Stent to Demonstrate Superiority Over Market-Leading Stent in Clinical Trials, Now Available in United States for

Treatment of Coronary Artery Disease

ABBOTT PARK, Ill., July 2 /PRNewswire-FirstCall/ -- Abbott today announced that the U.S. Food and Drug Administration (FDA) approved the XIENCE(TM) V Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease. XIENCE V is the only drug eluting stent to have demonstrated superiority over Boston Scientific's TAXUS(R) paclitaxel-eluting coronary stent system in two randomized head-to-head clinical trials. XIENCE V will be launched in the United States immediately.

"XIENCE V represents an important treatment advance for the estimated 13 million people in the United States suffering from coronary artery disease, and we believe XIENCE V will quickly become the new standard for drug eluting stents given its outstanding clinical results," said John M. Capek, Ph.D., executive vice president, Medical Devices, Abbott. "Physicians in the United States have been waiting for years to treat their patients with a technology that delivers on the promise of drug eluting stents through both ease of use and excellent clinical performance, and XIENCE V is that technology."

The XIENCE V drug coated stent is used to treat coronary artery disease by propping open a narrowed or blocked artery and releasing the drug, everolimus, in a controlled manner to prevent the artery from becoming blocked again following a stent procedure. Coronary artery disease occurs when plaque build- up narrows the arteries and reduces blood flow to the heart, which can lead to chest pain or a heart attack.

"XIENCE V was designed to improve safety and efficacy compared to earlier generation stents. The long-term clinical data from two studies performed in both the United States and Europe have now confirmed that XIENCE V is a true next-generation drug elu
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. FDA Approves ACIPHEX(R) (rabeprazole sodium) 20 mg for Short-Term Treatment of GERD in Adolescents
2. FDA Approves CONCERTA(R) (methylphenidate HCI) Extended-release Tablets for Treatment of ADHD (Attention Deficit Hyperactivity Disorder) in Adults
3. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry
4. Big Win for Biodiesel: ASTM Approves New Biodiesel Blend Specifications
5. FDA Approves GlaxoSmithKlines AVODART(R) in Combination with Tamsulosin for the Treatment of Symptomatic Enlarged Prostate
6. Arpida Annual General Meeting of Shareholders Approves All Board Proposals
7. FDA Approves MIXJECT(TM), a Convenient, Easy-to-Use Drug Delivery System For Watson Pharmaceuticals TRELSTAR(R) DEPOT and TRELSTAR(R) LA
8. FDA Approves VYVANSE(TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults
9. Maryland Approves Medicaid Reimbursement for ActiPatch(R)
10. Healthcare Coalition Approves Tools to Improve Patient Safety During Transitions of Care
11. Medicare Approves in Home Sleep Apnea Testing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... EXTON, Pa. , May 23, 2013 /PRNewswire/ ... leading research and advisory firms for specialized biopharmaceutical ... gastroenterologists, hepatologists, and infectious disease specialists reported that ... warehousing patients (e.g., intentionally delaying treatment) in anticipation ... physicians than six months ago, when only 6 ...
(Date:5/23/2013)... Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and ... a teleconference to discuss its First Quarter 2013 financial ... information is provided below: Date: Thursday, May ... Dial-in: (800) 875-3456 (U.S.); (800) 648-0973 ( ... For those unable to participate in the ...
(Date:5/23/2013)... DC (PRWEB) May 23, 2013 ... genetics-based ancestry tracing for people of African descent, ... Admixture product offering. For people of all races, ... make-up from five distinct populations: Indigenous Americas (Native ... and India Subcontinent. , Originally launched ...
(Date:5/23/2013)... 23, 2013 Just released this month on ... and author Barbara Roche: “Commit to Confidence: 30 Strategies ... with helpful tips and quotes from the fields of psychology ... tangible exercises that readers can do on their own or ... their personal and professional goals. , “My book ...
Breaking Biology Technology:The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 2The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 3Pressure BioSciences, Inc. to Discuss First Quarter 2013 Financial Results and Provide Business Update 2AfricanAncestry.com Rolls Out Improved MyDNAMix Admixture Test for People of all Races; Enhancements Increase Accuracy in Estimation of Ancestral Makeup 2AfricanAncestry.com Rolls Out Improved MyDNAMix Admixture Test for People of all Races; Enhancements Increase Accuracy in Estimation of Ancestral Makeup 3
... to Remain as Advisor to Company, FRAZER, Pa., ... its Executive Vice President, General Counsel &,Secretary, John E. ... effective March 31. Mr. Osborn has agreed to remain ... policy matters., "John has been an invaluable member ...
... Inc. (Nasdaq:,EVVV) will release its 2007 fourth quarter and ... market trading hours., The company will host a ... CT (8:30 a.m. ET). ev3 management will review its ... outlook, followed,by a question and answer session., The ...
... Spanish . , ANN ARBOR, Mich.---A new ... to operate a portable GPS locator, a cell phone, ... involving the University of Michigan shows. , A report ... issue of the journal Science. Authors include researchers from ...
Cached Biology Technology:Cephalon General Counsel John E. Osborn to Resign Position 2Cephalon General Counsel John E. Osborn to Resign Position 3ev3 Inc. to Report 2007 Fourth Quarter and Full-Year Financial Results and Host Conference Call on February 22, 2008 2Knee brace generates electricity from walking 2
(Date:5/22/2013)... feared Legionella pneumophila bacteria is responsible for ... In order to infect us, this pathogen has developed ... go unnoticed in our cells, thus avoiding these acting ... Basque biosciences research centre, CIC bioGUNE, in which teams ... USA and the National Supercomputation Centre in Barcelona (BSC) ...
(Date:5/22/2013)... 2013 Early screening for prostate cancer could become ... for women, thanks to UC Irvine research published today ... . , After more than a decade of work, ... identify clinically usable markers for prostate cancer in urine, ... with greater accuracy and at dramatically lower cost. The ...
(Date:5/22/2013)... YORK, May 22, 2013. Plastic additives known as ... about everywhere: They turn up in flooring, plastic ... to the Centers for Disease Control and Preventionthe ... phthalates have come under increasing scrutiny. A growing ... (which can leech from packaging and mix with ...
Breaking Biology News(10 mins):Mechanism discovered which aids Legionella to camouflage itself in the organism 2UCI chemists devise inexpensive, accurate way to detect prostate cancer 2UCI chemists devise inexpensive, accurate way to detect prostate cancer 3Study links chemicals widely found in plastics and processed food to elevated blood pressure in children and teens 2
... that methadone, an agent used to break addiction to ... including treatment resistant forms of the cancer. Their ... Cancer Research , a journal of the American ... as a new therapy for leukemia, especially in patients ...
... study by researchers at The University of Texas Medical School ... the current practice of retesting women during their second pregnancies ... for the infection previously. Group B Streptococcus, or GBS, ... carriers but in some cases can be deadly to an ...
... chemists have found a way to pull pure oxygen ... chemicals and a room-temperature glass of water. ,Because ... proposed using solar electricity to split water into those ... down. One of the chief obstacles to that green-energy ...
Cached Biology News:Lab study shows methadone breaks resistance in untreatable forms of leukemia 2Recurrence of group B strep high in subsequent pregnancies, say UT Houston obstetricians 2Water refineries? 2Water refineries? 3
... (GST) is commonly used as a fusion ... (1). The GSTTag sequence has been reported ... cases the solubility of its fusion partners. ... form, GSTTag fusion proteins can be purified ...
a1-Antitrypsin (human, alpha-1 AT)...
... The 7500ce meets the demands of the ... high performance from reliable, robust and simple ... detection power in the most challenging sample ... is equally suited to the toughest analytical ...
... Do you need to make your ... transformation efficiency? Take advantage of Lucigen’s unrivalled ... Custom Competent Cell Service offers: ... transformation efficiencies Fast turnaround ...
Biology Products: